The New Frontier of Immuno-Oncology
Pionyr Immunotherapeutics is a clinical stage company developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity.
About Pionyr Immunotherapeutics
The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering, or “tuning”, the myeloid infiltrate of the tumor microenvironment with high specificity and for very specific purposes.
Pionyr’s Myeloid TuningTM technology builds on the discovery that altering the tumor microenvironment to favor immune-activating cells over immune-suppressing cells enhances the body’s ability to combat cancer.
Pionyr has a deep and diversified pipeline of myeloid targeting monoclonal antibody therapeutics. The PY314 and PY159 programs, targeting TREM2 and TREM1 respectively, have been cleared by the FDA to initiate clinical trials.
Become a Pionyr
Pionyr Immunotherapeutics is currently seeking individuals with myeloid biology, immunology, assay development, in vivo pharmacology, DMPK, or translational science expertise to help advance our lead programs into clinical testing.
Academic Drug Discovery Consortium
Webinar on BioentrepreneurshipApril 10-15, 2021 and May 17-21, 2021
AACR Annual Meeting, Virtual
Pionyr Poster PresentationJuly 19-21, 2021
PEGS Summer Symposium, Virtual
November 18, 2020
Pionyr Immunotherapeutics Initiates Phase 1 Clinical Study of PY314